Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
11/29/23 BioVie (BIVI) NE3107 for Alzheimer's Disease (AD) Subscribers Only Subscribers Only Subscribers Only
11/29/23 BiomX (PHGE) BX004 for Cystic Fibrosis (CF) Subscribers Only Subscribers Only Subscribers Only
11/29/23 AbbVie (ABBV) Telisotuzumab Vedotin for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
11/27/23 Aldeyra (ALDX) Reproxalap for Dry Eye (Ophthalmology) Subscribers Only Subscribers Only Subscribers Only
11/27/23 Xenon Pharmaceutials (XENE) XEN1101 for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
11/30/23 Subscribers Only Subscribers Only Partnership - Acquisition Completion
12/02/23 Subscribers Only Subscribers Only Trial Data - Top-Line Results
12/02/23 Subscribers Only Subscribers Only Trial Data - Updated Results
12/02/23 Subscribers Only Subscribers Only Trial Data - Updated Results
12/02/23 Subscribers Only Subscribers Only Trial Data - Updated Results
Back to the top Back to the top